Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 1;44(4):e124-e126.
doi: 10.1097/INF.0000000000004630. Epub 2024 Nov 26.

Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World Study

Eric Jeziorski  1   2 , Antoine Ouziel  1   3 , Marie Cotillon  1   4 , Constance Bridonneau  5 , Etienne Bizot  1   6 , Clément Basse  7 , Aurélie Portefaix  8 , François Dubos  9 , Stéphane Béchet  10 , Lea Domitien  2 , Carine Jaillet  2 , Sorin Abrudan  11 , Rolf Kramer  11 , Vincent Gajdos  1   6 , Elise Launay  1   5 , Romain Basmaci  1   4   12 , Yves Gillet  1   3 , Robert Cohen  1   10   13   9 , Corinne Levy  1   10   13   9
Affiliations

Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World Study

Eric Jeziorski et al. Pediatr Infect Dis J. .

Abstract

Regarding nirsevimab immunization status, among 1085 infants hospitalized for bronchiolitis, the odds of hospitalization for respiratory syncytial virus bronchiolitis were 4.7 times higher for nonimmunized children. Immunized infants were less likely to require oxygen supplementation (20.2% vs. 30.6%, P = 0.02) and had a 1-day shorter hospital stay. Respiratory syncytial virus bronchiolitis was less frequent and less severe in infants immunized with nirsevimab.

Trial registration: ClinicalTrials.gov NCT06112132.

PubMed Disclaimer

Conflict of interest statement

E.J. received personal fees from Pfizer, GSK and Sanofi and nonfinancial support from MSD, Sanofi outside the submitted work. R.C. received personal fees and nonfinancial support from Pfizer and personal fees from Merck, GSK, Sanofi and AstraZeneca outside the submitted work. C.L. received personal fees and nonfinancial support from Pfizer and Merck outside the submitted work. S.A. and R.K. are employed at Sanofi and hold shares of the company. The other authors have no conflicts of interest to disclose.

References

    1. Hammitt LL, Dagan R, Yuan Y, et al. ; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837–846. - PubMed
    1. Ares-Gomez S, Mallah N, Santiago-Perez MI, et al. . Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024;24:817–828. - PubMed
    1. Assad Z. ENVIE. N Engl J Med. 2024;391:144. - PubMed
    1. Coma E, Martinez-Marcos M, Hermosilla E, et al. . Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). Arch Dis Child. 2024;109:736. - PMC - PubMed
    1. Ernst C, Bejko D, Gaasch L, et al. . Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024;29:2400033. - PMC - PubMed

MeSH terms

Substances

Associated data